Omics Technologies
ActiveSummary
Omics Technologies has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16,715 and a net result of €1,773. Equity is shrinking by about 31% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2028. Its solvency ranks better than 40% of 13,511 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
08-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Back to profitnet €1,773
Net result €1,773 after 3 loss-making years.
17-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 31 days late
2023
31-12
Financial
Weakest financial yearnet -€15,278
Net result drops to -€15,278, the lowest in the series; recovery starts the following year.
27-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 27 days late
2022
19-10
NBB filing
Annual accounts filed
financial year 2021 · micro format · 80 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.